This approval follows the pivotal Phase 3 EPCORE® FL-1 trial, which showed that the TEPKINLY combination significantly reduced the risk of disease progression or death by 79 percent compared to the standard R2 treatment.
The trial results underscore the potential of TEPKINLY to offer a more effective treatment option for patients with this condition.
Follicular lymphoma is a slow-growing type of non-Hodgkin lymphoma originating from B-cell lymphocytes and is the second most common form of NHL, accounting for 20-30 percent of all cases.
Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, commented, “This approval is important because it brings an effective treatment option to patients across Europe, representing meaningful progress for patients with follicular lymphoma.”
